drugset
Drugs / rATG
last change Feb 2026 re-read 2 minutes ago

rATG

Protein / enzyme biologic

Developed for
bone marrow failure syndrome · congenital amegakaryocytic thrombocytopenia · Diamond-Blackfan anemia · GATA2 deficiency with susceptibility to MDS/AML · inherited sideroblastic anemia · paroxysmal nocturnal hemoglobinuria · SAMD9-related spectrum and myeloid neoplasm risk · SAMD9L-related spectrum and myeloid neoplasm risk
+1 more · Shwachman-Diamond syndrome
Investigated by
Blood and Marrow Transplant Clinical Trials Network · Fred Hutchinson Cancer Center · National Cancer Institute (NCI) · National Heart, Lung, and Blood Institute (NHLBI) · National Marrow Donor Program

Trials 1 · a red edge is where a trial was stopped

today NCT04965597 · Ph 2
2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04965597 Apr 2022 → Feb 2026 Diamond-Blackfan anemia, GATA2 deficiency with susceptibility to MDS/AML, SAMD9-related spectrum and myeloid neoplasm risk, SAMD9L-related spectrum and myeloid neoplasm risk +5 Fred Hutchinson Cancer Center Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as rATG “rabbit antithymocyte globulin (rATG) work when given before a blood or bone marrow transplant” NCT04965597 ↗
Modality Protein / enzyme biologic “lapine T-lymphocyte immune globulin (rATG) IV over 4-6 hours” NCT04965597 ↗
Route Intravenous “Given IV” NCT04965597 ↗